If you experience painful periods alongside your PMDD symptoms, this study sheds light on why common pain relievers like ibuprofen don't always work well enough — and what other biological processes might be driving that pain.
Researchers studied 51 adolescents within three years of getting their first period. They collected menstrual fluid samples and measured levels of prostaglandins and other inflammatory molecules called oxylipins. They found that a specific prostaglandin called PGF2α was significantly higher in those with period pain compared to those without. However, the link between PGF2α levels and how much pain someone felt was only moderate, meaning prostaglandins alone don't fully explain menstrual pain.
One surprising finding: adolescents who were already taking NSAIDs (like ibuprofen) actually had higher PGF2α levels than those who weren't taking any pain medication. Previous research suggests NSAIDs work best when started before or right at the beginning of a period and taken consistently for several days — which isn't how most teens use them. This could mean the timing and consistency of pain reliever use really matters.
Perhaps most interesting, the researchers used advanced analysis to identify several other inflammatory molecules — including leukotrienes and other compounds from different biological pathways — that were elevated in those with pain. This suggests that period pain involves a wider web of inflammation than previously understood, not just the prostaglandin pathway that NSAIDs target. The authors suggest that future treatments combining medications that block multiple inflammatory pathways could provide better relief. While this study focused on period pain rather than PMDD specifically, many people with PMDD also deal with significant menstrual pain, so these findings may help explain part of that experience.
Key findings
- Adolescents with dysmenorrhea had significantly higher PGF2α concentrations in menstrual effluent (median 4.5 ng/mL) compared to pain-free controls (median 1.1 ng/mL, p = 0.014)
- The correlation between PGF2α concentration and menstrual pain intensity was modest (r = 0.37, p = 0.004), suggesting prostaglandins are not the sole mediators of menstrual pain
- Differences in PGE2 (p = 0.053) and 12-HETE (p = 0.305) between dysmenorrhea and control groups were not statistically significant
- UHPLC-MS analysis identified six additional elevated inflammatory metabolites in dysmenorrhea participants (12-HETrE, 14,15-EET, 15-HETE, 18-cdLTB4, LTB4, PGF2α) and one decreased metabolite (6-kPGF1α)
- NSAID users with dysmenorrhea paradoxically had higher PGF2α levels (66.2 ng/mL) than non-NSAID users (19.1 ng/mL, p = 0.04), suggesting current NSAID use patterns may be insufficient
- Eicosanoid concentrations were positively correlated with menstrual effluent volume (r's > 0.4, p's < 0.001)
Methods, briefly
Prospective cohort study of N=51 adolescents (33 with dysmenorrhea, 18 pain-free controls) within 3 years of menarche, enrolled in the EMPATHY project. Participants provided overnight menstrual effluent samples (tampon or pad) between 4 and 30 months after menarche. Eicosanoid concentrations (PGE2, PGF2α, 12-HETE) were measured by ELISA. A subset (n=10; 5 highest pain, 5 pain-free) underwent UHPLC-MS/MS analysis for 76 eicosanoid and oxylipin metabolites. Menstrual pain was assessed using 0-10 numerical rating scales. Nonparametric statistical tests were used (Kruskal-Wallis, Spearman correlations).
Limitations to keep in mind
- Overnight menstrual pain intensity was relatively low in the sample, potentially limiting the dynamic range of pain-eicosanoid associations
- UHPLC-MS analysis was limited to only 10 participants due to cost, precluding reliable correction for multiple comparisons
- PGE2 ELISA showed cross-reactivity with PGE1 and PGE3, and poor correlation with UHPLC-MS measurements (r = 0.27)
- High coefficients of variation for eicosanoid concentrations (PGF2α: 136%, PGE2: 289%, 12-HETE: 262%) even after adjusting for group differences
- Sample collection window (4-30 months post-menarche) was constrained by funding rather than biological rationale for the upper limit
- Single overnight sample collection may not capture full menstrual cycle eicosanoid dynamics
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.